Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24952876 | 1.00 | SCD (0.46) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24953957 | 1.00 | SCD (0.46) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24953915 | 0.94 | SCD (0.47) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24953825 | 0.91 | SCD (0.48) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24953917 | 0.90 | SCD (0.49) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24953971 | 0.90 | SCD (0.49) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24953921 | 0.90 | SCD (0.49) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24953740 | 0.84 | NPC1 (0.58) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL24952880 | 0.84 | SCD (0.51) | SCDLMNANPC1RAB9AMEN1 | |
| SCHEMBL24846105 | 0.83 | GLS (0.44) | LMNAMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | SCD 2396/4885LMNA 4081/4885NPC1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.